Peripartum Cardiomyopathy: From Pathophysiology to Management

Front-Matter_2021_Peripartum-Cardiomyopathy
Front Matter
Copyright_2021_Peripartum-Cardiomyopathy
Copyright
Contributors_2021_Peripartum-Cardiomyopathy
Contributors
Preface_2021_Peripartum-Cardiomyopathy
Preface
Acknowledgments_2021_Peripartum-Cardiomyopathy
Acknowledgments
Foreword_2021_Peripartum-Cardiomyopathy
Foreword
Chapter-1---Etiology-and-pathophysiology_2021_Peripartum-Cardiomyopathy
Etiology and pathophysiology
Genetics of PPCM
References
Chapter-2---How-to-diagnose-the-condition_2021_Peripartum-Cardiomyopathy
How to diagnose the condition
Clinical presentation
Investigations
Electrocardiography
Blood tests and biomarkers
Chest radiography
Transthoracic echocardiography
Cardiac magnetic resonance imaging
Genetic testing
Summary
References
Chapter-3---Risk-stratification-in-patients-newly-diagn_2021_Peripartum-Card
Risk stratification in patients newly diagnosed with peripartum cardiomyopathy
Patient characteristics
Age
Medical history
Onset and time of diagnosis
Hemodynamic parameters
ECG
Concomitant hypertension
Predictors of mortality and morbidity
Predictors of LV function recovery
Concomitant right ventricular dysfunction at diagnosis
Magnetic resonance imaging (MRI)
Other factors associated with lack of LV function recovery (ethnicity, biomarkers)
Ethnicity
Biomarkers
Genetic predictors
Summary
References
Chapter-4---How-to-manage-a-woman-presenting-with-_2021_Peripartum-Cardiomyo
How to manage a woman presenting with acute PPCM?
Introduction
Clinical presentation and evaluation of acute PPCM
Management of acute PPCM presenting with systemic congestion without cardiopulmonary distress
Initial management of acute PPCM with cardiopulmonary distress or hemodynamic instability
Advanced management of severe acute PPCM
References
Chapter-5---What-needs-to-be-known-about-longer-term-m_2021_Peripartum-Cardi
What needs to be known about longer-term management and prognosis?
Management
Beta-blocker
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Angiotensin receptor neprilysin inhibitor
Mineralocorticoid receptor antagonist
Ivabradine
Diuretics
Cardiac glycosides
Vasodilators
Nitrates
Anticoagulation
Heparin and synthetic pentasaccharides
Long-term therapy
General approach for follow-up
Devices
Wearable cardioverter-defibrillator
Implantable cardioverter-defibrillator and cardiac resynchronization therapy
Left ventricular assist device and heart transplantation
Other implantable electronic devices
Prognosis
Recovery of left ventricular function
Recovery at 6 months
Recovery beyond 6 months
Mortality
Predictors
Clinical parameters and genetics
Electrocardiogram
Laboratory parameters
Imaging
References
Chapter-6---Is-a-subsequent-pregnancy-safe-_2021_Peripartum-Cardiomyopathy
Is a subsequent pregnancy safe?
Maternal risk during a subsequent pregnancy
Fetal risk during a subsequent pregnancy
A practical approach to a subsequent pregnancy
Summary
References
Chapter-7---How-to-advise-on-safe-delivery-and-best-cont_2021_Peripartum-Car
How to advise on safe delivery and best contraception for patients with heart failure
Anticoagulation
Termination of pregnancy
Mode of delivery
Contraception
Summary
References
Chapter-8---What-can-be-learned-from-the-global-reg_2021_Peripartum-Cardiomy
What can be learned from the global registry on PPCM?
Background to the registry
Methodology
Challenges of setting up a biobank
Other overall challenges
Overall successes
Key findings from the registry
Lessons learned
References
Chapter-9---Setting-up-a-clinical-service-for-PPC_2021_Peripartum-Cardiomyop
Setting up a clinical service for PPCM in Iraq
Introduction
Peripartum cardiomyopathy in Iraq: What was known and how was dealing with?
Challenges and barriers during setting a new PPCM service in Iraq
Initiative for setting new PPCM service in Iraq
Plan for setting up a clinical service for PPCM in Iraq: Questions and answers
Impact of EORP-PPCM registry on the setting up a clinical service for PPCM in Iraq
Exceptional data from the real daily practice about subsequent pregnancies in patients with PPCM
Future plan for quality improvement of PPCM service in Iraq
Lessons to learn and keys of success
For the sake of history, messages to Prof. Karen Sliwa and ESC from Iraqi PPCM site
References
Chapter-10---Electrocardiographic-assessment-and-manageme_2021_Peripartum-Ca
Electrocardiographic assessment and management of arrhythmias in peripartum cardiomyopathy
Introduction
The 12‑lead electrocardiogram in PPCM
Ambulatory ECG monitoring in PPCM
Prevention and treatment of arrhythmias in PPCM
Implantable and wearable cardioverter defibrillators in PPCM
Conclusion
Acknowledgments
References
Chapter-11---Learning-from-the-peripartum-cardiomyopathy-in-_2021_Peripartum
Learning from the peripartum cardiomyopathy in Nigeria (PEACE) registry: A multisite, contemporary PPCM registry in Nigeria
Background
Summary of the study protocol
Clinical profile, incidence and risk factors of PPCM patients in Nigeria
Mortality of PPCM patients in Nigeria
Remodeling of cardiac chambers in PPCM patients in Nigeria
Selenium supplementation trial in PPCM
Relationship between serum selenium and ventricular dysfunction in apparently healthy pregnant women
Conclusion
References
Index_2021_Peripartum-Cardiomyopathy
Index
A
B
C
D
E
F
G
H
I
K
L
M
N
O
P
Q
R
S
T
U
V
W